Smart Flow Lab  |  Technology Analysis

Biotech Faces AI: Reshaping Pharma

By Mohamed Ismaili  •   •  Senior Technology Analyst, Smart Flow Lab  •  5 min read

AI-driven tech boosts drug discovery efficiency

Biotech Faces AI: Reshaping Pharma
Biotech Faces AI: Reshaping Pharma — Smart Flow Lab / June 22, 2026

While the pharmaceutical industry has traditionally been known for its lengthy and costly drug development process, recent advancements in biotechnology and AI-driven drug discovery are poised to significantly reshape the landscape of pharma, with estimates suggesting that the global automated liquid handling systems market alone will be worth USD 6.9 billion by 2035, growing at a 9.8% CAGR, according to a report by Healthcare Foresights published on GlobeNewswire. This raises an important question: how will these technological advancements impact the future of pharmaceutical research and development, and which companies will emerge as winners in this new landscape?

The Bigger Picture

The integration of AI in biotech has been gaining momentum, with companies like Insilico Medicine, which recently announced the completion of first-in-human dosing in a Phase I clinical study of an AI-driven NLRP3 inhibitor, as reported by PRNewswire. This development highlights the potential of AI to accelerate the drug discovery process, and its impact is being felt across the industry. Furthermore, the US Treasury's assessment of options to screen investments in China biotech, as reported by Crypto Briefing, may also have significant implications for global pharmaceutical collaborations and innovation.

Data In Focus

A closer look at the data reveals a significant shift in the pharmaceutical landscape. The preclinical imaging market, for example, is expected to reach USD 7.24 billion by 2035, driven by expanding pharmaceutical research and imaging biomarkers, according to a report by SNS Insider published on GlobeNewswire. Similarly, the nucleic acid testing market is projected to hit USD 8.42 billion by 2035, growing at a 6.57% CAGR, as molecular diagnostics and precision medicine adoption accelerate, as reported by GlobeNewswire. These numbers suggest that the industry is undergoing a significant transformation, driven by technological advancements and changing market dynamics.

Winners And Losers

As the pharmaceutical landscape continues to evolve, it is likely that some companies will emerge as winners, while others may struggle to adapt. Some of the key factors that will determine success in this new landscape include:

  • Investment in AI-driven drug discovery and development
  • Ability to navigate changing regulatory environments
  • Access to large datasets and advanced analytics capabilities
  • Strategic partnerships and collaborations with other industry players

Companies that are able to effectively leverage these factors will be well-positioned to succeed in the new pharmaceutical landscape, while those that fail to adapt may be left behind.

The integration of AI in biotech has the potential to significantly accelerate the drug discovery process, and we are already seeing the impact of this trend in the market. As the industry continues to evolve, it will be important for companies to stay ahead of the curve and invest in the technologies and strategies that will drive success in the future — Senior analyst, pharmaceutical sector

My Take: Biotech's AI-Driven Revolution

I firmly believe that the convergence of biotechnology and artificial intelligence is poised to revolutionize the pharmaceutical industry, with the global automated liquid handling systems market expected to reach USD 6.9 billion by 2035 at a 9.8% CAGR, as reported by Healthcare Foresights. However, contrary to the mainstream assumption that this trend will lead to unchecked growth, I think the US Treasury's heightened scrutiny of US-China biotech investments will introduce a significant layer of complexity, potentially slowing down global collaborations and innovation. The recent completion of first-in-human dosing in a Phase I clinical study of an AI-driven NLRP3 inhibitor by Insilico Medicine is a promising development, but it also underscores the need for a more nuanced understanding of the regulatory landscape. With the preclinical imaging market projected to reach USD 7.24 billion by 2035, driven by expanding pharmaceutical research, I will be watching closely over the next 6-12 months to see how these intersecting trends shape the future of drug discovery and development, particularly in light of the growing nucleic acid testing market, which is expected to hit USD 8.42 billion by 2035.

Bottom Line

In conclusion, the pharmaceutical industry is undergoing a significant transformation, driven by technological advancements in biotechnology and AI-driven drug discovery. As the industry continues to evolve, it will be important for companies to stay ahead of the curve and invest in the technologies and strategies that will drive success in the future. With the global automated liquid handling systems market expected to reach USD 6.9 billion by 2035, and the preclinical imaging market projected to reach USD 7.24 billion by 2035, it is clear that the pharmaceutical landscape will be shaped by these technological advancements, and companies that are able to effectively leverage these trends will be well-positioned to succeed.

📰 Sources & References

About the Author

Mohamed Ismaili
Senior Technology Analyst at Smart Flow Lab. Mohamed covers artificial intelligence, semiconductor markets, cybersecurity infrastructure, and global digital policy. He has tracked the intersection of technology and geopolitics for over a decade, with a focus on how emerging markets — particularly in Africa and the Middle East — are being reshaped by digital transformation. Based in Morocco.
Editorial Note: This analysis is based on publicly available industry information and recent news sources. All opinions expressed are those of the author and do not constitute financial or investment advice.